20004525

Source:http://linkedlifedata.com/resource/pubmed/id/20004525

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0376358, umls-concept:C1122962, umls-concept:C1442162, umls-concept:C1518409, umls-concept:C1519043, umls-concept:C1522449, umls-concept:C1550718
pubmed:issue	1
pubmed:dateCreated	2010-8-16
pubmed:abstractText	To estimate the safety and tolerability of daily administration of 250 mg of gefitinib given concurrently with three-dimensional conformal radiotherapy for patients with nonmetastatic prostate cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7603616
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1alpha, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6, http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha, http://linkedlifedata.com/resource/pubmed/chemical/epidermal growth factor receptor..., http://linkedlifedata.com/resource/pubmed/chemical/gefitinib
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1879-355X
pubmed:author	pubmed-author:CollanJuhaniJ, pubmed-author:HemminkiAkseliA, pubmed-author:IsolaJormaJ, pubmed-author:JoensuuGreettaG, pubmed-author:JoensuuTimoT, pubmed-author:KouriMauriM, pubmed-author:KupelianPatrick APA, pubmed-author:NokisalmiPetriP, pubmed-author:PesonenSariS, pubmed-author:ReddyChandanaC, pubmed-author:RuutuMirjaM
pubmed:copyrightInfo	Copyright (c) 2010 Elsevier Inc. All rights reserved.
pubmed:issnType	Electronic
pubmed:day	1
pubmed:volume	78
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	42-9
pubmed:meshHeading	pubmed-meshheading:20004525-Aged, pubmed-meshheading:20004525-Antineoplastic Agents, pubmed-meshheading:20004525-Combined Modality Therapy, pubmed-meshheading:20004525-Disease-Free Survival, pubmed-meshheading:20004525-Drug Administration Schedule, pubmed-meshheading:20004525-Humans, pubmed-meshheading:20004525-Interleukin-1alpha, pubmed-meshheading:20004525-Interleukin-6, pubmed-meshheading:20004525-Male, pubmed-meshheading:20004525-Maximum Tolerated Dose, pubmed-meshheading:20004525-Middle Aged, pubmed-meshheading:20004525-Neoplasm Proteins, pubmed-meshheading:20004525-Neoplasm Staging, pubmed-meshheading:20004525-Prostate-Specific Antigen, pubmed-meshheading:20004525-Prostatic Neoplasms, pubmed-meshheading:20004525-Quinazolines, pubmed-meshheading:20004525-Radiotherapy Dosage, pubmed-meshheading:20004525-Receptor, Epidermal Growth Factor, pubmed-meshheading:20004525-Tumor Necrosis Factor-alpha
pubmed:year	2010
pubmed:articleTitle	A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer.
pubmed:affiliation	Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I